Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGAM1 | P18669 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22011812 | 0.94 | HTR2C (0.32) | CNR2HTR2CHTR2AHTR2BHTR4 | |
| SCHEMBL22011196 | 0.89 | CNR2 (0.32) | CNR2CNR1RIPK1 | |
| SCHEMBL22010982 | 0.87 | CNR2 (0.36) | CNR2HTR2CHTR2AHTR2BCNR1 | |
| SCHEMBL22011218 | 0.85 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL22010959 | 0.85 | RIPK1 (0.32) | CNR2HTR2CHTR2AHTR2BCNR1 | |
| SCHEMBL22010791 | 0.84 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL22010822 | 0.84 | PGAM1 (0.33) | PGAM1CNR2CNR1 | |
| SCHEMBL15445794 | 0.82 | RIPK1 (0.38) | CNR2HTR2CHTR2AHTR2BPDE4A | |
| SCHEMBL28697245 | 0.82 | RIPK1 (0.38) | CNR2HTR2CHTR2AHTR2BPDE4A | |
| SCHEMBL22011817 | 0.82 | RIPK1 (0.30) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | PGAM1 4829/4885CNR2 1838/4885HTR2C 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.